Oculopharyngeal Muscular Dystrophy Treatment Market Gambling Life-size Growth ThPosted by Ashish on December 18th, 2019 Oculopharyngeal Muscular Dystrophy (OPMD) is muscle disorder mainly affects the muscle of upper eye lids and throat. It is genetic condition characterized by muscle weakness and generally begins in adulthood. Oculopharyngeal muscular dystrophy is among the 30 inherited diseases declared by WHO and it result in weakening and worsening of muscles. According to US Library of medicine, In Europe, the estimated prevalence of oculopharyngeal muscular dystrophy is 1 in 100,000 people. In French and Canadian population, it is more common where it is estimated to affect 1 in 1,000 individuals. Rising prevalence of oculopharyngeal muscular dystrophy is anticipated to push the growth of oculopharyngeal muscular dystrophy treatment market during forecast period. In February 2019, ‘Seelos Therapeutics’ a major key player involved in Oculopharyngeal Muscular Dystrophy treatment market, made an agreement with Bioblast Pharma Ltd., to acquire all development and commercial rights to Bioblast’s proprietary drug named trehalose which is predominantly used to treat Oculopharyngeal Muscular Dystrophy. Oculopharyngeal Muscular Dystrophy treatment market is mainly contain various conventional drug therapies and novel gene therapies. Most of the novel therapies are under the product pipeline of major key players present in Oculopharyngeal Muscular Dystrophy treatment market. Major driving factor involved in oculopharyngeal muscular dystrophy treatment market is increased prevalence of oculopharyngeal muscular dystrophy in middle aged population. The conventional therapy mainly focused on symptomatic treatment of Oculopharyngeal Muscular Dystrophy and having lots of off target effects, this factor providing the additional opportunity for key players present in oculopharyngeal muscular dystrophy treatment market to expand their research and development activities and expected to drive the growth of oculopharyngeal muscular dystrophy treatment market. Additionally, introduction of new disease-modifying and novel drugs therapies, increased drug development activities are expected to drive the oculopharyngeal muscular dystrophy treatment market. Furthermore, gene therapies such as mutation suppression, exon skipping are also anticipated to push the oculopharyngeal muscular dystrophy treatment market during forecast period. Get Sample Copy of This Report @ https://www.persistencemarketresearch.com/samples/30707 On the contrary, high cost of the novel therapies and lack of awareness among individuals are some factor that are expected to hamper the growth of oculopharyngeal muscular dystrophy treatment market. The global Oculopharyngeal Muscular Dystrophy Treatment Market is segmented based on the treatment type, drug class, dosage form, and distribution channel. By treatment type, the global Oculopharyngeal Muscular Dystrophy Treatment Market is segmented as:
By drug class, the global Oculopharyngeal Muscular Dystrophy Treatment Market is segmented as:
By dosage form, the global Oculopharyngeal Muscular Dystrophy Treatment Market is segmented as:
By Distribution channel, the global Oculopharyngeal Muscular Dystrophy Treatment Market is segmented as:
Get Methodology of This Report @ https://www.persistencemarketresearch.com/methodology/30707 The key participants operating in the global Oculopharyngeal Muscular Dystrophy Treatment Market are: Bioblast Pharma , BioMarin, PTC Therapeutics, NS Pharma,Inc, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc., Marathon Pharmaceuticals, Fibrogen Inc, Bristol-Myers Squibb, Sarepta Therapeutics, GSK and others. The report covers exhaustive analysis on:
Regional analysis includes
Report Highlights:
Like it? Share it! More by this author |